期刊
CANCER TREATMENT REVIEWS
卷 41, 期 10, 页码 914-924出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.09.006
关键词
Immunotherapy; Programmed death-1; Cytotoxic T-Iymphocyte antigen-4; Mesothelioma; Immune checkpoint
类别
资金
- Belgian Foundation Against Cancer [FA/2014/263]
- Research Foundation Flanders [1510215N]
- Agency for Innovation through Science and Technology fellowship [141433]
Malignant pleural mesothelioma is an aggressive cancer linked to asbestos exposure in most patients. Due to the long latency between exposure and presentation, incidence is expected to further increase in the next decade, despite the ban on asbestos import which occurred at the end of last century in industrialized countries. Platinum-based palliative chemotherapy is the only treatment with proven benefit on outcome, resulting in selected patients in a median overall survival of about I year. Therefore, there is room for therapeutic improvement using a new strategy to prolong survival. Dealing with cancer cell induced immunosuppression is a promising approach. Reactivating immune responses that are silenced by immune checkpoints recently gained a lot of interest. Checkpoint blockade has already shown promising preclinical and clinical results in several cancer types and is currently also being investigated in mesothelioma. Here, we discuss the expression patterns and mechanisms of action of CTLA-4 and PD-1 as the two most studied and of TIM-3 and LAG-3 as two interesting upcoming immune checkpoints. Furthermore, we review the clinical results of molecules blocking these immune checkpoints and point out their future opportunities with a special focus on mesothelioma. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据